Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

@article{Hallberg2013MechanisticII,
  title={Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology},
  author={Bengt Hallberg and Ruth H. Palmer},
  journal={Nature Reviews Cancer},
  year={2013},
  volume={13},
  pages={685-700}
}
The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for… 
Anaplastic lymphoma tyrosine kinase oncogene in human cancer: gene aberrations, methods of detection and therapeutic potential
TLDR
Critical issues related to ALK-targeting therapy, including ALK gene aberrations, methods of detection, mechanism of acquired resistance and second-generation ALK inhibitors are reviewed.
ALK: a tyrosine kinase target for cancer therapy
TLDR
This review outlines the recent developments in the understanding and treatment of tumors with ALK alterations and proposes targeting strategies to counteract the newly emergent mechanism(s) of ALK inhibitor resistance.
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal
An update of ALK inhibitors in human clinical trials.
TLDR
The current understanding of ALK signaling, genomic aberrations in cancer and emerging mechanisms of drug resistance are summarized and all ALK inhibitors are summarized.
Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
  • Hao Huang
  • Biology, Chemistry
    International journal of molecular sciences
  • 2018
TLDR
A mini-review of different features of ALK, a membrane-bound tyrosine kinase, and some recent research advances on ALK fusion proteins in cancers are summarized.
ALK-driven tumors and targeted therapy: focus on crizotinib
TLDR
Although more studies are required to establish selective targeting of ALK as a definitive therapeutic option, initial trials have shown extraordinary results in the majority of cases.
Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
TLDR
The molecular mechanisms of cancer stem cells in mediating resistance to ALK inhibitors as well as the current understanding of the molecular challenges in targeting ALK in ALK-expressing human cancers will be discussed.
The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes
TLDR
This review will focus on the basic molecular pathology of ALK gene rearrangement in NSCLC, current testing methods, treatment strategies against ALK-positive and crizotinib-resistant NSCLCs.
...
...

References

SHOWING 1-10 OF 220 REFERENCES
Anaplastic lymphoma kinase in human cancer.
TLDR
The current understanding of ALK in human cancer and the implication of recent results for treatment are discussed.
Anaplastic lymphoma kinase in human cancer.
TLDR
This review describes the expression of the ALK-RTK, its related fusion proteins, and their molecular mechanisms of activation and novel tailored strategies are briefly illustrated for the treatment of ALk-positive neoplasms.
The anaplastic lymphoma kinase in the pathogenesis of cancer
TLDR
This Review will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.
Identification of anaplastic lymphoma kinase fusions in renal cancer
TLDR
In this context, ALK inhibitor therapy would constitute a therapeutic advance, as has previously been demonstrated with lung cancer, inflammatory myofibroblastic tumors, and anaplastic large cell lymphomas.
Inhibition of ALK Signaling for Cancer Therapy
TLDR
The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations.
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
TLDR
The discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor are reported.
ALK and NSCLC: Targeted therapy with ALK inhibitors
TLDR
Results from recent clinical trials provide hope for NSCLC patients harboring oncogenic translocations involving the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase, and suggest a step forward in the diagnosis and treatment of ALK-positiveNSCLC.
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
TLDR
Findings from a series of lung cancer patients with acquired resistance to the ALK TKI crizotinib reinforce the need to tailor therapeutic strategies to the specific underlying drug resistance mechanisms in the tumors to improve clinical outcomes.
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.
TLDR
It is shown that the anaplastic lymphoma kinase (ALK) is aberrantly activated in ovarian cancer and ALK is identified as a potential therapeutic target in a subset of serous ovarian carcinoma and stromal sarcoma patients.
Anaplastic lymphoma kinase as a therapeutic target
TLDR
Current understandings about the ALK tyrosine kinase and its implication in the oncogenesis of human cancers as a fusion protein or through mutations are described and its interest as a therapeutic target is discussed.
...
...